NATIONAL QUALITY FORUM

Measure Evaluation 4.1
January 2010

This form contains the measure information submitted by stewards. Blank fields indicate no information was provided. Attachments also may have been submitted and are provided to reviewers. The sub-criteria and most of the footnotes from the evaluation criteria are provided in Word comments and will appear if your cursor is over the highlighted area (or in the margin if your Word program is set to show revisions in balloons). Hyperlinks to the evaluation criteria and ratings are provided in each section.

TAP/Workgroup (if utilized)**:** Complete all yellow highlighted areas of the form. Evaluate the extent to which each sub-criterion is met. Based on your evaluation, summarize the strengths and weaknesses in each section.

Note: *If there is no TAP or workgroup, the SC also evaluates the* sub-criteria *(yellow highlighted areas)*.

Steering Committee: Complete all pink highlighted areas of the form. Review the workgroup/TAP assessment of the sub-criterion, noting any areas of disagreement; then evaluate the extent to which each major criterion is met; and finally, indicate your recommendation for the endorsement. Provide the rationale for your ratings.

Evaluation ratings of the extent to which the criteria are met
C = Completely (unquestionably demonstrated to meet the criterion)
P = Partially (demonstrated to partially meet the criterion)
M = Minimally (addressed BUT demonstrated to only minimally meet the criterion)
N = Not at all (NOT addressed; OR incorrectly addressed; OR demonstrated to NOT meet the criterion)
NA = Not applicable (only an option for a few sub-criteria as indicated)

(for NQF staff use) **NQF Review** #: PSM-019-10 **NQF Project:** Patient Safety Measures

MEASURE DESCRIPTIVE INFORMATION
De.1 Measure Title: Patient(s) with rheumatoid arthritis taking methotrexate, sulfasalazine, gold, or leflunomide that had a CBC in last 3 reported months.
De.2 Brief description of measure*:* This measure identifies individuals with rheumatoid arthritis, 2 years of age or older, taking taking methotrexate, sulfasalazine, gold, or leflunomide that had a CBC test in last 3 months of the report period.
1.1-2 Type of Measure: process **De.3 If included in a composite or paired with another measure, please identify composite or paired measure** Does not apply.
De.4 National Priority Partners Priority Area: safety **De.5 IOM Quality Domain**: equity **De.6 Consumer Care Need:** Staying Healthy

CONDITIONS FOR CONSIDERATION BY NQF	
Four conditions must be met before proposed measures may be considered and evaluated for suitability as voluntary consensus standards:	**NQF Staff**
A. The measure is in the public domain or an intellectual property (measure steward agreement) is signed. *Public domain only applies to governmental organizations. All non-government organizations must sign a measure steward agreement even if measures are made publicly and freely available.* **A.1 Do you attest that the measure steward holds intellectual property rights to the measure and the right to use aspects of the measure owned by another entity (e.g., risk model, code set)?** Yes **A.2 Indicate if Proprietary Measure** (*as defined in measure steward agreement*)**:** proprietary measure **A.3 Measure Steward Agreement:** agreement signed and submitted	**A** **Y**☐ **N**☐

A.4 Measure Steward Agreement attached: Measure Steward Addendum_Ingenix 012010.doc	
B. The measure owner/steward verifies there is an identified responsible entity and process to maintain and update the measure on a schedule that is commensurate with the rate of clinical innovation, but at least every 3 years. Yes, information provided in contact section	**B** Y☐ N☐
C. The intended use of the measure includes both public reporting and quality improvement. ►**Purpose:** public reporting, quality improvement Payment Incentive, Accountability	**C** Y☐ N☐
D. The requested measure submission information is complete. Generally, measures should be fully developed and tested so that all the evaluation criteria have been addressed and information needed to evaluate the measure is provided. Measures that have not been tested are only potentially eligible for a time-limited endorsement and in that case, measure owners must verify that testing will be completed within 12 months of endorsement. **D.1Testing:** Yes, fully developed and tested **D.2 Have NQF-endorsed measures been reviewed to identify if there are similar or related measures?** Yes	**D** Y☐ N☐
(for NQF staff use) **Have all conditions for consideration been met?** **Staff Notes to Steward** (*if submission returned*)**:**	**Met** Y☐ N☐
Staff Notes to Reviewers (*issues or questions regarding any criteria*)**:**	
Staff Reviewer Name(s):	

TAP/Workgroup Reviewer Name:	
Steering Committee Reviewer Name:	
1. IMPORTANCE TO MEASURE AND REPORT	
Extent to which the specific measure focus is important to making significant gains in health care quality (safety, timeliness, effectiveness, efficiency, equity, patient-centeredness) and improving health outcomes for a specific high impact aspect of healthcare where there is variation in or overall poor performance. *Measures must be judged to be important to measure and report in order to be evaluated against the remaining criteria.* (evaluation criteria) **1a. High Impact**	Eval Rating
(for NQF staff use) **Specific NPP goal**:	
1a.1 Demonstrated High Impact Aspect of Healthcare: patient/societal consequences of poor quality **1a.2** **1a.3 Summary of Evidence of High Impact:** The prevalence of rheumatoid arthritis (RA) among adults is approximately 1 percent (1). The majority of patients with RA use nonbiologic disease-modifying antirheumatic drugs (DMARDs) and the prevalence of DMARD use is rising rapidly (2). While more aggressive DMARD use is recommended and is now standard of care, safety issues associated with these medications is a concern (2). DMARDS have also been associated with significant adverse events. When patients take these medications, routine laboratory monitoring is recommended to maximize clinical benefit and reduce the risk of side effects and toxicity (3-5). Hematological toxicities have been reported with several disease modifying medications used to treat RA (3-5). Since these adverse events can be addressed through drug discontinuation, dose reduction, or other interventions, routine laboratory monitoring is recommended. This includes laboratory monitoring of the CBC (3-5). **1a.4 Citations for Evidence of High Impact:** 1. Scott DL, Kingsley GH. Tumor necrosis factor inhibitors for rheumatoid arthritis. N Engl J Med 2006;355:704–12. 2. Pressman Lovinger S. Use of biologics for rheumatoid arthritis tempered by concerns over safety, cost.	**1a** C☐ P☐ M☐ N☐

JAMA 2003;289:3229–30.
3. Saag KG, Teng GG, Patkar NM, et.al. American College of Rheumatology 2008 Recommendations for the Use of Nonbiologic and Biologic Disease-Modifying Antirheumatic Drugs in Rheumatoid Arthritis. Arthritis and Rheumatism (Arthritis Care and Research)2008;59(6):762-84.
4. American College of Rheumatology's Starter Set of Measures for Quality in the Care for Rheumatic and Musculoskeletal Diseases, February 2006. Accessed January 18, 2010. URL: http://www.rheumatology.org/practice/qmc/starterset0206.asp
5. Antirheumatic agents. Drug Facts and Comparisons. eFacts [online]. 2009. Available from Wolters Kluwer Health, Inc. Accessed January 18, 2010.

1b. Opportunity for Improvement

1b.1 Benefits (improvements in quality) envisioned by use of this measure: CBC monitoring can identify the presence of treatment related adverse events (e.g., anemia, low white counts that can increase the risk of infections, low platelet counts that can increase the risk of bleeding). Identification of an adverse event can be addressed through drug discontinuation, dose reduction, or other interventions. This can prevent more serious adverse events, improve medication compliance, and ultimately improve outcomes such as quality of life and disease control.

1b.2 Summary of data demonstrating performance gap (variation or overall poor performance) across providers:
Using a geographically diverse 15 million member benchmark database (this database represents predominately a commercial population less than 65 year of age) the compliance rate was 66.6 percent, indicating a clear gap in care and opportunity for care improvement.

1b.3 Citations for data on performance gap:
Ingenix EBM Connect benchmark results, September 2009

1b.4 Summary of Data on disparities by population group:
None

1b.5 Citations for data on Disparities:

1b
C☐
P☐
M☐
N☐

1c. Outcome or Evidence to Support Measure Focus

1c.1 Relationship to Outcomes (*For non-outcome measures, briefly describe the relationship to desired outcome. For outcomes, describe why it is relevant to the target population*)**:** The primary outcome is to improve the safety and efficacy of treatment with selected immunomodulators. CBC monitoring allows detection or adverse events that can be managed with drug discontinuation, dose reductions, or other interventions. This can prevent more serious adverse events and improve treatment outcomes.

1c.2-3. Type of Evidence: evidence based guideline, expert opinion, other (specify) pharmaceutical manufacturer

1c.4 Summary of Evidence (*as described in the criteria; for outcomes, summarize any evidence that healthcare services/care processes influence the outcome*)**:**
Hematological toxicities have been reported with several disease modifying medications used to treat ulcerative colitis (1-3). Since these adverse events can be addressed through drug discontinuation, dose reduction, or other interventions, routine laboratory monitoring is recommended. This includes laboratory monitoring of the CBC (1-3).

The pharmaceutical manufacturers recommend monitoring for hematological toxicities as follows: at least monthly for patients taking methotrexate, frequently for 6 months following initiation of sulfasalazine and then at least once every 3 months thereafter, at least monthly for patients taking oral gold, every 2 weeks for patients taking intramuscular (IM) gold, and monthly for 6 months following initiation of leflunomide and then every 6 to 8 weeks thereafter (3).

1c
C☐
P☐
M☐
N☐

In addition, the American College of Rheumatology has published monitoring recommendations. ACR 2008 guidelines recommend a CBC at least every 12 weeks in patients have been taking methotrexate, sulfasalazine, or leflunamide for more than 6 months (more frequent CBC monitoring is recommended during the initial 6 months of treatment(1). The ACR 2006 start set document recommends the following routine CBC monitoring: every 8 weeks for patients taking methotrexate, every 12 weeks for patients taking sulfasalazine, every 8 weeks for patients taking leflunaminde, every 8 weeks for patients take IM gold, and every 12 weeks for patients taking oral gold (2).

1c.5 Rating of strength/quality of evidence (*also provide narrative description of the rating and by whom***):**
There is no strength of evidence provided with this recommendation. Recommendations are based on consensus expert opinion.

1c.6 Method for rating evidence:

1c.7 Summary of Controversy/Contradictory Evidence: No rigorous research has define the appropriate screening interval for these medications. Screening recommendations are based on consensus expert opinion. When the pharmaceutical manufacturer and the ACR recommendations differed, the more conservative timeframe for monitoring was used.

1c.8 Citations for Evidence (*other than guidelines***):** 3. Antirheumatic agents. Drug Facts and Comparisons. eFacts [online]. 2009. Available from Wolters Kluwer Health, Inc. Accessed January 18, 2010.

1c.9 Quote the Specific guideline recommendation (*including guideline number and/or page number***):**
ACR 2008 (1): "Beyond 3 months of therapy with leflunomide, methotrexate,
or sulfasalazine, monitoring with complete blood count, a chemistry panel, and determination of the serum creatinine levels was recommended every 8–12 weeks. Beyond 6 months of therapy, the longer time interval (e.g., 12 weeks) of the monitoring recommendation was suggested." [page 775, also see table same page that summarizes these recommedations]

ACR 2006 Starter Set (2): Table 2, page 6, summarizes the recommendations for several medications including methotrexate, sulfasalazine, leflunamide, IM gold, and oral gold:
Methotrexate - hemoglobin/hematocrit, WBC, platelet count every 8 weeks
Sulfasalazine - hemoglobin/hematocrit, WBC, platelet count every 12 weeks
Leflunamide - hemoglobin/hematocrit, WBC, platelet count every 8 weeks
IM Gold - hemoglobin/hematocrit, WBC, platelet count every 8 weeks
Oral Gold - - hemoglobin/hematocrit, WBC, platelet count every 12 weeks

1c.10 Clinical Practice Guideline Citation: 1. Saag KG, Teng GG, Patkar NM, et.al. American College of Rheumatology 2008
Recommendations for the Use of Nonbiologic and Biologic Disease-Modifying Antirheumatic Drugs in Rheumatoid Arthritis. Arthritis and Rheumatism (Arthritis Care and Research)2008;59(6):762-84.
2. American College of Rheumatology's Starter Set of Measures for Quality in the Care for Rheumatic and Musculoskeletal Diseases, February 2006. Accessed January 18, 2010. URL:
http://www.rheumatology.org/practice/qmc/starterset0206.asp
1c.11 National Guideline Clearinghouse or other URL:
http://www.rheumatology.org/publications/guidelines/index.asp AND
http://www.rheumatology.org/practice/qmc/starterset0206.asp

1c.12 Rating of strength of recommendation (*also provide narrative description of the rating and by whom***):**
There is no strength of evidence provided with this recommendation. Recommendations are based on consensus expert opinion.

1c.13 Method for rating strength of recommendation (*If different from* USPSTF system*, also describe*

rating and how it relates to USPSTF): 1c.14 **Rationale for using this guideline over others:** The 2006 and 2008 ACR guidelines are the only published guidelines that address the recommended monitoring of DMARDS. ACR is a nationally recognized specialty organization.	
TAP/Workgroup: What are the strengths and weaknesses in relation to the sub-criteria **for** *Importance to Measure and Report?*	**1**
Steering Committee: Was the threshold criterion, *Importance to Measure and Report*, **met?** **Rationale:**	**1** **Y☐** **N☐**
2. SCIENTIFIC ACCEPTABILITY OF MEASURE PROPERTIES	
Extent to which the measure, as specified, produces consistent (reliable) and credible (valid) results about the quality of care when implemented. (evaluation criteria)	Eval Rating
2a. MEASURE SPECIFICATIONS	
S.1 **Do you have a web page where current detailed measure specifications can be obtained?** S.2 **If yes, provide web page URL:** **2a. Precisely Specified**	
2a.1 **Numerator Statement (***Brief, text description of the numerator - what is being measured about the target population, e.g. target condition, event, or outcome***):** Patients who are diagnosed with rheumatoid arthritis and who are taking methotrexate, sulfasalazine, gold, or leflunomide, who have had a CBC test during the following time period: last 90 days of the report period through 90 days after the end of the report period 2a.2 **Numerator Time Window (***The time period in which cases are eligible for inclusion in the numerator***):** Last 90 days of the report period through 90 days after the end of the report period 2a.3 **Numerator Details (***All information required to collect/calculate the numerator, including all codes, logic, and definitions***):** Patients who have had a CBC test (code set PR0013) during the following time period: last 90 days of the report period through 90 days after the end of the report period Code Set Code Set Description Procedure Code PR0013 CBC 80050 PR0013 CBC 80055 PR0013 CBC 85021 PR0013 CBC 85022 PR0013 CBC 85023 PR0013 CBC 85024 PR0013 CBC 85025 PR0013 CBC 85027 PR0013 CBC 85031	
2a.4 **Denominator Statement (***Brief, text description of the denominator - target population being measured***):** Patients 2 years of age or older who are diagnosed with rheumatoid arthritis and who are being actively treated with methotrexate, sulfasalazine, gold, or leflunomide 2a.5 **Target population gender:** Female, Male 2a.6 **Target population age range:** Patients 2 years of age or older at the end of the report period	**2a-specs** **C☐** **P☐** **M☐** **N☐**

2a.7 Denominator Time Window (*The time period in which cases are eligible for inclusion in the denominator***):**
The 24 months prior to the end of the report period for confirmation that the patient had rheumatoid arthritis; last 120 days of the report period through 90 days after the end of the report period for confirmation that the patient was actively taking methotrexate, sulfasalazine, gold, or leflunomide

2a.8 Denominator Details (*All information required to collect/calculate the denominator - the target population being measured - including all codes, logic, and definitions***):**
Criteria for inclusion in the denominator are as follows:
1. All males or females that are 2 years of age or older at the end of the report period
2. Patient must have been continuously enrolled in medical benefits throughout the 12 months prior to the end of the report period AND pharmacy benefit plan for 12 months prior to the end of the report period. The standard EBM Connect® enrollment break logic allows unlimited breaks in coverage of no more than 45 days and no breaks greater than 45 days.
3. The patient is listed in the Disease Registry Input File for this condition.

OR

Patients who fulfill either criteria A or criteria B (or both)

A. During the 24 months prior to the end of the report period, the patient has two or more of the following services or events, at least 14 days apart, with a diagnosis of rheumatoid arthritis (DX0134):

- Professional Encounter code set (PR0107 or RV0107)
- Professional Supervision code set (PR0108)
- Facility Event – Confinement/Admission (i.e., hospital admission)
- Facility Event – Emergency Room
- Facility Event – Outpatient Surgery

AND

During the 12 month report period, the patient has one or more of the following services or events, with a diagnosis of rheumatoid arthritis (DX0134):

- Professional Encounter code set (PR0107 or RV0107)
- Professional Supervision code set (PR0108)
- Facility Event – Confinement/Admission (i.e., hospital admission)
- Facility Event – Emergency Room
- Facility Event – Outpatient Surgery

B. During the 24 months prior to the end of the report period, the patient has one or more of the following services or events, with a diagnosis of rheumatoid arthritis (DX0134):

- Professional Encounter code set (PR0107 or RV0107)
- Professional Supervision code set (PR0108)
- Facility Event – Confinement/Admission (i.e., hospital admission)
- Facility Event – Emergency Room
- Facility Event – Outpatient Surgery

AND the patient has filled 2 or more prescriptions for the following medications during the 12 month report period: tumor necrosis factor inhibitors (code set RX-13), leflunomide (code set RX-16), injectable gold salts (code set RX-53), oral gold salts (code set RX-54), anakinra (code set RX-66), methotrexate (code set RX-75), plaquenil (code set RX-96), sulfasalazine (code set RX-113), abatacept (code set RX-233), rituximab (code set RX-234)

4. The patient must have filled a prescription for one of the following medications during the last 120 days of the report period through 90 days after the end of the report period, with a duration of treatment greater than 90 days:

- leflunomide (code set RX-16)
- injectable gold salts (code set RX-53)
- oral gold salts (code set RX-54)
- methotrexate (code set RX-75)
- sulfasalazine (code set RX-113)

Code Set	Code Set Description	Diagnosis Code
DX0134	Rheumatoid arthritis	714.0
DX0134	Rheumatoid arthritis	714.1
DX0134	Rheumatoid arthritis	714.2

DX0134	Rheumatoid arthritis	714.3
DX0134	Rheumatoid arthritis	714.30
DX0134	Rheumatoid arthritis	714.31
DX0134	Rheumatoid arthritis	714.32
DX0134	Rheumatoid arthritis	714.33
DX0134	Rheumatoid arthritis	714.4
DX0134	Rheumatoid arthritis	714.81

Code Set	Code Set Description	Procedure Code
PR0107	Professional encounter	99201
PR0107	Professional encounter	99202
PR0107	Professional encounter	99203
PR0107	Professional encounter	99204
PR0107	Professional encounter	99205
PR0107	Professional encounter	99211
PR0107	Professional encounter	99212
PR0107	Professional encounter	99213
PR0107	Professional encounter	99214
PR0107	Professional encounter	99215
PR0107	Professional encounter	99217
PR0107	Professional encounter	99218
PR0107	Professional encounter	99219
PR0107	Professional encounter	99220
PR0107	Professional encounter	99221
PR0107	Professional encounter	99222
PR0107	Professional encounter	99223
PR0107	Professional encounter	99231
PR0107	Professional encounter	99232
PR0107	Professional encounter	99233
PR0107	Professional encounter	99234
PR0107	Professional encounter	99235
PR0107	Professional encounter	99236
PR0107	Professional encounter	99238
PR0107	Professional encounter	99239
PR0107	Professional encounter	99241
PR0107	Professional encounter	99242
PR0107	Professional encounter	99243
PR0107	Professional encounter	99244
PR0107	Professional encounter	99245
PR0107	Professional encounter	99251
PR0107	Professional encounter	99252
PR0107	Professional encounter	99253
PR0107	Professional encounter	99254
PR0107	Professional encounter	99255
PR0107	Professional encounter	99261
PR0107	Professional encounter	99262
PR0107	Professional encounter	99263
PR0107	Professional encounter	99271
PR0107	Professional encounter	99272
PR0107	Professional encounter	99273
PR0107	Professional encounter	99274
PR0107	Professional encounter	99275
PR0107	Professional encounter	99281
PR0107	Professional encounter	99282
PR0107	Professional encounter	99283
PR0107	Professional encounter	99284
PR0107	Professional encounter	99285
PR0107	Professional encounter	99301

PR0107	Professional encounter	99302
PR0107	Professional encounter	99303
PR0107	Professional encounter	99304
PR0107	Professional encounter	99305
PR0107	Professional encounter	99306
PR0107	Professional encounter	99307
PR0107	Professional encounter	99308
PR0107	Professional encounter	99309
PR0107	Professional encounter	99310
PR0107	Professional encounter	99311
PR0107	Professional encounter	99312
PR0107	Professional encounter	99313
PR0107	Professional encounter	99315
PR0107	Professional encounter	99316
PR0107	Professional encounter	99318
HR0107	Professional encounter	99341
PR0107	Professional encounter	99342
PR0107	Professional encounter	99343
PR0107	Professional encounter	99344
PR0107	Professional encounter	99345
PR0107	Professional encounter	99347
PR0107	Professional encounter	99348
PR0107	Professional encounter	99349
PR0107	Professional encounter	99350
PR0107	Professional encounter	99381
PR0107	Professional encounter	99382
PR0107	Professional encounter	99383
PR0107	Professional encounter	99384
PR0107	Professional encounter	99385
PR0107	Professional encounter	99386
PR0107	Professional encounter	99387
PR0107	Professional encounter	99391
PR0107	Professional encounter	99392
PR0107	Professional encounter	99393
PR0107	Professional encounter	99394
PR0107	Professional encounter	99395
PR0107	Professional encounter	99396
PR0107	Professional encounter	99397
PR0107	Professional encounter	99401
PR0107	Professional encounter	99402
PR0107	Professional encounter	99403
PR0107	Professional encounter	99404
PR0107	Professional encounter	99411
PR0107	Professional encounter	99412
PR0107	Professional encounter	99420
PR0107	Professional encounter	99429
PR0107	Professional encounter	S0270
PR0107	Professional encounter	S0271
PR0107	Professional encounter	S0272
PR0107	Professional encounter	S0273

Code Set	Code Set Description	Procedure Code
PR0108	Professional supervision	99321
PR0108	Professional supervision	99322
PR0108	Professional supervision	99323
PR0108	Professional supervision	99324
PR0108	Professional supervision	99325
PR0108	Professional supervision	99326

PR0108	Professional supervision 99327
PR0108	Professional supervision 99328
PR0108	Professional supervision 99331
PR0108	Professional supervision 99332
PR0108	Professional supervision 99333
PR0108	Professional supervision 99334
PR0108	Professional supervision 99335
PR0108	Professional supervision 99336
PR0108	Professional supervision 99337
PR0108	Professional supervision 99339
PR0108	Professional supervision 99340
PR0108	Professional supervision 99371
PR0108	Professional supervision 99372
PR0108	Professional supervision 99373
PR0108	Professional supervision 99374
PR0108	Professional supervision 99375
PR0108	Professional supervision 99377
PR0108	Professional supervision 99378
PR0108	Professional supervision 99379
PR0108	Professional supervision 99380
PR0108	Professional supervision 99441
PR0108	Professional supervision 99442
PR0108	Professional supervision 99443
PR0108	Professional supervision 99444
PR0108	Professional supervision G0179
PR0108	Professional supervision G0180
PR0108	Professional supervision G0181
PR0108	Professional supervision G0182

Code Set	Code Set Description	Revenue Code
RV0107	Professional encounter	0510
RV0107	Professional encounter	0511
RV0107	Professional encounter	0512
RV0107	Professional encounter	0513
RV0107	Professional encounter	0514
RV0107	Professional encounter	0515
RV0107	Professional encounter	0516
RV0107	Professional encounter	0517
RV0107	Professional encounter	0519
RV0107	Professional encounter	0520
RV0107	Professional encounter	0521
RV0107	Professional encounter	0522
RV0107	Professional encounter	0523
RV0107	Professional encounter	0524
RV0107	Professional encounter	0525
RV0107	Professional encounter	0526
RV0107	Professional encounter	0528
RV0107	Professional encounter	0529
RV0107	Professional encounter	0981
RV0107	Professional encounter	0983

Rx code set	Code set description	ndc
RX-13	Tumor Necrosis Factor inhibitors	00074379901
RX-13	Tumor Necrosis Factor inhibitors	00074379902
RX-13	Tumor Necrosis Factor inhibitors	00074433902
RX-13	Tumor Necrosis Factor inhibitors	00074433906
RX-13	Tumor Necrosis Factor inhibitors	00074433907
RX-13	Tumor Necrosis Factor inhibitors	00074937402

RX-13	Tumor Necrosis Factor inhibitors	50474070062
RX-13	Tumor Necrosis Factor inhibitors	50474071079
RX-13	Tumor Necrosis Factor inhibitors	54569552400
RX-13	Tumor Necrosis Factor inhibitors	54868478200
RX-13	Tumor Necrosis Factor inhibitors	54868482200
RX-13	Tumor Necrosis Factor inhibitors	54868544400
RX-13	Tumor Necrosis Factor inhibitors	57894003001
RX-13	Tumor Necrosis Factor inhibitors	57894007001
RX-13	Tumor Necrosis Factor inhibitors	57894007002
RX-13	Tumor Necrosis Factor inhibitors	58406042534
RX-13	Tumor Necrosis Factor inhibitors	58406042541
RX-13	Tumor Necrosis Factor inhibitors	58406043501
RX-13	Tumor Necrosis Factor inhibitors	58406043504
RX-13	Tumor Necrosis Factor inhibitors	58406044501
RX-13	Tumor Necrosis Factor inhibitors	58406044504
RX-13	Tumor Necrosis Factor inhibitors	58406045501
RX-13	Tumor Necrosis Factor inhibitors	58406045504

Rx code set	Code set description	ndc
RX-16	Leflunomide	00088216030
RX-16	Leflunomide	00088216130
RX-16	Leflunomide	00088216203
RX-16	Leflunomide	00093017356
RX-16	Leflunomide	00093017456
RX-16	Leflunomide	00555035101
RX-16	Leflunomide	00555035201
RX-16	Leflunomide	00781505631
RX-16	Leflunomide	00781505731
RX-16	Leflunomide	49884088805
RX-16	Leflunomide	49884088811
RX-16	Leflunomide	49884088905
RX-16	Leflunomide	49884088911
RX-16	Leflunomide	54868231900
RX-16	Leflunomide	54868438500
RX-16	Leflunomide	54868490200
RX-16	Leflunomide	60505250201
RX-16	Leflunomide	60505250203
RX-16	Leflunomide	60505250301
RX-16	Leflunomide	60505250303
RX-16	Leflunomide	66993016030
RX-16	Leflunomide	66993016130
RX-16	Leflunomide	68115081730

Rx code set	Code set description	ndc
RX-53	Gold salts (injectable only)	00006776210
RX-53	Gold salts (injectable only)	00006776264
RX-53	Gold salts (injectable only)	00006776364
RX-53	Gold salts (injectable only)	00006776464
RX-53	Gold salts (injectable only)	00085046003
RX-53	Gold salts (injectable only)	00418445001
RX-53	Gold salts (injectable only)	00418445010
RX-53	Gold salts (injectable only)	00418445021
RX-53	Gold salts (injectable only)	11098051101
RX-53	Gold salts (injectable only)	11098051110
RX-53	Gold salts (injectable only)	11098053301
RX-53	Gold salts (injectable only)	11098053310
RX-53	Gold salts (injectable only)	51309092102
RX-53	Gold salts (injectable only)	51309092202

RX-53	Gold salts (injectable only)	51309092302
RX-53	Gold salts (injectable only)	51309092310
RX-53	Gold salts (injectable only)	51309092410
RX-53	Gold salts (injectable only)	54569197101
RX-53	Gold salts (injectable only)	54569257600
RX-53	Gold salts (injectable only)	54643010010
RX-53	Gold salts (injectable only)	54643010050
RX-53	Gold salts (injectable only)	54643010060
RX-53	Gold salts (injectable only)	54643010070
RX-53	Gold salts (injectable only)	54643100060
RX-53	Gold salts (injectable only)	54643100500
RX-53	Gold salts (injectable only)	54643100600
RX-53	Gold salts (injectable only)	54643100700
RX-53	Gold salts (injectable only)	54868113300
RX-53	Gold salts (injectable only)	58441112401
RX-53	Gold salts (injectable only)	60793010910
RX-53	Gold salts (injectable only)	61147800600
RX-53	Gold salts (injectable only)	61147800603
RX-53	Gold salts (injectable only)	66758001101
RX-53	Gold salts (injectable only)	66758001102
RX-53	Gold salts (injectable only)	66758001103
RX-53	Gold salts (injectable only)	66758002601

Rx code set	Code set description	ndc
RX-54	Gold salts (oral only)	00007487918
RX-54	Gold salts (oral only)	54569146600
RX-54	Gold salts (oral only)	58016067860
RX-54	Gold salts (oral only)	63032001160
RX-54	Gold salts (oral only)	65483009306

Rx code set	Code set description	ndc
RX-66	Anakinra	55513017701
RX-66	Anakinra	55513017707
RX-66	Anakinra	55513017728

Rx code set	Code set description	ndc
RX-75	Methotrexate	00005450704
RX-75	Methotrexate	00005450705
RX-75	Methotrexate	00005450707
RX-75	Methotrexate	00005450709
RX-75	Methotrexate	00005450723
RX-75	Methotrexate	00005450791
RX-75	Methotrexate	00005455426
RX-75	Methotrexate	00013222686
RX-75	Methotrexate	00013223686
RX-75	Methotrexate	00013224686
RX-75	Methotrexate	00013225686
RX-75	Methotrexate	00013226686
RX-75	Methotrexate	00013226691
RX-75	Methotrexate	00013227666
RX-75	Methotrexate	00013227686
RX-75	Methotrexate	00013227691
RX-75	Methotrexate	00013228686
RX-75	Methotrexate	00013228691
RX-75	Methotrexate	00013229686
RX-75	Methotrexate	00013229691
RX-75	Methotrexate	00015300620
RX-75	Methotrexate	00015300697

RX-75	Methotrexate	00015300720
RX-75	Methotrexate	00015300797
RX-75	Methotrexate	00015300820
RX-75	Methotrexate	00015300897
RX-75	Methotrexate	00015305020
RX-75	Methotrexate	00015305097
RX-75	Methotrexate	00015305120
RX-75	Methotrexate	00015305197
RX-75	Methotrexate	00015305220
RX-75	Methotrexate	00015305297
RX-75	Methotrexate	00015305320
RX-75	Methotrexate	00015305397
RX-75	Methotrexate	00054455015
RX-75	Methotrexate	00054455025
RX-75	Methotrexate	00054855003
RX-75	Methotrexate	00054855005
RX-75	Methotrexate	00054855006
RX-75	Methotrexate	00054855007
RX-75	Methotrexate	00054855010
RX-75	Methotrexate	00054855025
RX-75	Methotrexate	00094532553
RX-75	Methotrexate	00094532561
RX-75	Methotrexate	00094532569
RX-75	Methotrexate	00182153901
RX-75	Methotrexate	00182153989
RX-75	Methotrexate	00182153995
RX-75	Methotrexate	00186142013
RX-75	Methotrexate	00186142113
RX-75	Methotrexate	00186142212
RX-75	Methotrexate	00186142304
RX-75	Methotrexate	00205450723
RX-75	Methotrexate	00205455426
RX-75	Methotrexate	00205455626
RX-75	Methotrexate	00205456123
RX-75	Methotrexate	00205465302
RX-75	Methotrexate	00205465490
RX-75	Methotrexate	00205466692
RX-75	Methotrexate	00205520394
RX-75	Methotrexate	00205532526
RX-75	Methotrexate	00205532618
RX-75	Methotrexate	00205532719
RX-75	Methotrexate	00205532730
RX-75	Methotrexate	00205533734
RX-75	Methotrexate	00205533798
RX-75	Methotrexate	00205533834
RX-75	Methotrexate	00205933792
RX-75	Methotrexate	00205933894
RX-75	Methotrexate	00304218155
RX-75	Methotrexate	00304218256
RX-75	Methotrexate	00304218358
RX-75	Methotrexate	00364249901
RX-75	Methotrexate	00364249936
RX-75	Methotrexate	00378001401
RX-75	Methotrexate	00378001450
RX-75	Methotrexate	00405464301
RX-75	Methotrexate	00405464336
RX-75	Methotrexate	00418014820
RX-75	Methotrexate	00418014920

RX-75	Methotrexate	00418015220
RX-75	Methotrexate	00418019702
RX-75	Methotrexate	00418019704
RX-75	Methotrexate	00418019708
RX-75	Methotrexate	00418021502
RX-75	Methotrexate	00418021602
RX-75	Methotrexate	00469148040
RX-75	Methotrexate	00469149040
RX-75	Methotrexate	00469152040
RX-75	Methotrexate	00469197010
RX-75	Methotrexate	00469197020
RX-75	Methotrexate	00469197030
RX-75	Methotrexate	00469215010
RX-75	Methotrexate	00469216010
RX-75	Methotrexate	00469288030
RX-75	Methotrexate	00536399801
RX-75	Methotrexate	00536399836
RX-75	Methotrexate	00555057202
RX-75	Methotrexate	00555057235
RX-75	Methotrexate	00555057245
RX-75	Methotrexate	00555057246
RX-75	Methotrexate	00555057247
RX-75	Methotrexate	00555057248
RX-75	Methotrexate	00555057249
RX-75	Methotrexate	00555092701
RX-75	Methotrexate	00555092801
RX-75	Methotrexate	00555092901
RX-75	Methotrexate	00555094501
RX-75	Methotrexate	00603449921
RX-75	Methotrexate	00677161001
RX-75	Methotrexate	00719154410
RX-75	Methotrexate	00781107601
RX-75	Methotrexate	00781107636
RX-75	Methotrexate	00839790506
RX-75	Methotrexate	00904174960
RX-75	Methotrexate	00904174973
RX-75	Methotrexate	00904601260
RX-75	Methotrexate	10019094001
RX-75	Methotrexate	10019094002
RX-75	Methotrexate	10019094101
RX-75	Methotrexate	10139006202
RX-75	Methotrexate	10139006210
RX-75	Methotrexate	10139006240
RX-75	Methotrexate	11845110401
RX-75	Methotrexate	21695011100
RX-75	Methotrexate	23490588900
RX-75	Methotrexate	38779003503
RX-75	Methotrexate	38779003504
RX-75	Methotrexate	38779003506
RX-75	Methotrexate	38779003510
RX-75	Methotrexate	38779003511
RX-75	Methotrexate	38779003515
RX-75	Methotrexate	38779003525
RX-75	Methotrexate	49452460001
RX-75	Methotrexate	49452460002
RX-75	Methotrexate	49452460003
RX-75	Methotrexate	49452460101
RX-75	Methotrexate	49452460102

RX-75	Methotrexate	49452460103
RX-75	Methotrexate	49452460104
RX-75	Methotrexate	49999038024
RX-75	Methotrexate	51079067001
RX-75	Methotrexate	51079067005
RX-75	Methotrexate	51079067086
RX-75	Methotrexate	51079067087
RX-75	Methotrexate	51079067088
RX-75	Methotrexate	51079067089
RX-75	Methotrexate	51285036601
RX-75	Methotrexate	51285036701
RX-75	Methotrexate	51285036801
RX-75	Methotrexate	51285036901
RX-75	Methotrexate	51285050902
RX-75	Methotrexate	51309020605
RX-75	Methotrexate	51309020610
RX-75	Methotrexate	51309020615
RX-75	Methotrexate	51309020705
RX-75	Methotrexate	51309020710
RX-75	Methotrexate	51309020715
RX-75	Methotrexate	51309020720
RX-75	Methotrexate	51309020830
RX-75	Methotrexate	51309020930
RX-75	Methotrexate	51309021030
RX-75	Methotrexate	51309021130
RX-75	Methotrexate	51432052203
RX-75	Methotrexate	51552105401
RX-75	Methotrexate	51552105409
RX-75	Methotrexate	51927156500
RX-75	Methotrexate	52728035401
RX-75	Methotrexate	52728035532
RX-75	Methotrexate	52959024400
RX-75	Methotrexate	53002048720
RX-75	Methotrexate	53258148004
RX-75	Methotrexate	53258149004
RX-75	Methotrexate	53258152004
RX-75	Methotrexate	53258197001
RX-75	Methotrexate	53258197002
RX-75	Methotrexate	53258197003
RX-75	Methotrexate	53258288003
RX-75	Methotrexate	53258288030
RX-75	Methotrexate	53443000321
RX-75	Methotrexate	53443000322
RX-75	Methotrexate	53443000324
RX-75	Methotrexate	53443058232
RX-75	Methotrexate	53905003110
RX-75	Methotrexate	53905003210
RX-75	Methotrexate	53905003310
RX-75	Methotrexate	53905003410
RX-75	Methotrexate	54569140700
RX-75	Methotrexate	54569155000
RX-75	Methotrexate	54569181800
RX-75	Methotrexate	54569181801
RX-75	Methotrexate	54569181802
RX-75	Methotrexate	54569181803
RX-75	Methotrexate	54569181804
RX-75	Methotrexate	54569181805
RX-75	Methotrexate	54569181806

RX-75	Methotrexate	54569181807
RX-75	Methotrexate	54569181808
RX-75	Methotrexate	54569181809
RX-75	Methotrexate	54569184601
RX-75	Methotrexate	54569452500
RX-75	Methotrexate	54569498300
RX-75	Methotrexate	54569531600
RX-75	Methotrexate	54868017300
RX-75	Methotrexate	54868017301
RX-75	Methotrexate	54868382600
RX-75	Methotrexate	54868382601
RX-75	Methotrexate	54868382602
RX-75	Methotrexate	54868382603
RX-75	Methotrexate	54868382604
RX-75	Methotrexate	54868382605
RX-75	Methotrexate	54868382606
RX-75	Methotrexate	54868382607
RX-75	Methotrexate	54868471600
RX-75	Methotrexate	54868479600
RX-75	Methotrexate	54868480900
RX-75	Methotrexate	55084097520
RX-75	Methotrexate	55289092430
RX-75	Methotrexate	55390003110
RX-75	Methotrexate	55390003210
RX-75	Methotrexate	55390003310
RX-75	Methotrexate	55390003410
RX-75	Methotrexate	55390014301
RX-75	Methotrexate	58406067101
RX-75	Methotrexate	58406067103
RX-75	Methotrexate	58406067105
RX-75	Methotrexate	58406067301
RX-75	Methotrexate	58406068114
RX-75	Methotrexate	58406068117
RX-75	Methotrexate	58406068312
RX-75	Methotrexate	58406068316
RX-75	Methotrexate	58406068318
RX-75	Methotrexate	58469039983
RX-75	Methotrexate	58469399830
RX-75	Methotrexate	59911587401
RX-75	Methotrexate	61703035038
RX-75	Methotrexate	61703040707
RX-75	Methotrexate	61703040732
RX-75	Methotrexate	61703040804
RX-75	Methotrexate	61703040807
RX-75	Methotrexate	61703040813
RX-75	Methotrexate	61703040822
RX-75	Methotrexate	61703040832
RX-75	Methotrexate	61703040841
RX-75	Methotrexate	61703040858
RX-75	Methotrexate	62584078201
RX-75	Methotrexate	62701094036
RX-75	Methotrexate	62701094099
RX-75	Methotrexate	62991120001
RX-75	Methotrexate	62991120002
RX-75	Methotrexate	63323012102
RX-75	Methotrexate	63323012104
RX-75	Methotrexate	63323012108
RX-75	Methotrexate	63323012110

RX-75	Methotrexate	63323012140
RX-75	Methotrexate	63323012250
RX-75	Methotrexate	63323012302
RX-75	Methotrexate	63323012310
RX-75	Methotrexate	63370015410
RX-75	Methotrexate	63370015415
RX-75	Methotrexate	63370015425
RX-75	Methotrexate	66479013501
RX-75	Methotrexate	66479013509
RX-75	Methotrexate	66479013611
RX-75	Methotrexate	66479013613
RX-75	Methotrexate	66479013619
RX-75	Methotrexate	66479013721
RX-75	Methotrexate	66479013929
RX-75	Methotrexate	66758004002
RX-75	Methotrexate	66758004008
RX-75	Methotrexate	66758004101
RX-75	Methotrexate	67253032010
RX-75	Methotrexate	67253032036
RX-75	Methotrexate	67253058042
RX-75	Methotrexate	67253058043
RX-75	Methotrexate	67253058044
RX-75	Methotrexate	67253058045
RX-75	Methotrexate	67253058046
RX-75	Methotrexate	68115063200

Rx code set	Code set description	ndc
RX-96	Plaquenil	00024156104
RX-96	Plaquenil	00024156210
RX-96	Plaquenil	00093977401
RX-96	Plaquenil	00093977405
RX-96	Plaquenil	00143212801
RX-96	Plaquenil	00182260901
RX-96	Plaquenil	00364262701
RX-96	Plaquenil	00378037301
RX-96	Plaquenil	00406209601
RX-96	Plaquenil	00406209605
RX-96	Plaquenil	00440761530
RX-96	Plaquenil	00536571001
RX-96	Plaquenil	00591069801
RX-96	Plaquenil	00591069805
RX-96	Plaquenil	00603394421
RX-96	Plaquenil	00677159001
RX-96	Plaquenil	00781140701
RX-96	Plaquenil	00781140705
RX-96	Plaquenil	00839796306
RX-96	Plaquenil	00904510760
RX-96	Plaquenil	00955079001
RX-96	Plaquenil	00955079005
RX-96	Plaquenil	17236061001
RX-96	Plaquenil	17236061005
RX-96	Plaquenil	23490572403
RX-96	Plaquenil	23490572406
RX-96	Plaquenil	23490572409
RX-96	Plaquenil	23629002601
RX-96	Plaquenil	23629002610
RX-96	Plaquenil	29936037701
RX-96	Plaquenil	38245077410

RX-96	Plaquenil	38245077450
RX-96	Plaquenil	49999037260
RX-96	Plaquenil	51875037701
RX-96	Plaquenil	51875037702
RX-96	Plaquenil	52544069801
RX-96	Plaquenil	52544069805
RX-96	Plaquenil	52555064201
RX-96	Plaquenil	52761037701
RX-96	Plaquenil	52959017660
RX-96	Plaquenil	53002048560
RX-96	Plaquenil	54569146800
RX-96	Plaquenil	54569146801
RX-96	Plaquenil	54569498100
RX-96	Plaquenil	54569498101
RX-96	Plaquenil	54569861600
RX-96	Plaquenil	54868382100
RX-96	Plaquenil	54868382101
RX-96	Plaquenil	54868382102
RX-96	Plaquenil	54868382103
RX-96	Plaquenil	55175503101
RX-96	Plaquenil	55887091601
RX-96	Plaquenil	57866902701
RX-96	Plaquenil	60429070030
RX-96	Plaquenil	60429070060
RX-96	Plaquenil	62269025024
RX-96	Plaquenil	62269025029
RX-96	Plaquenil	62269140701
RX-96	Plaquenil	63304029601
RX-96	Plaquenil	63304029605
RX-96	Plaquenil	65162061010
RX-96	Plaquenil	65243025518
RX-96	Plaquenil	67544098180
RX-96	Plaquenil	68084026901
RX-96	Plaquenil	68084026911
RX-96	Plaquenil	68115063300
RX-96	Plaquenil	68258906301
RX-96	Plaquenil	68382009601
RX-96	Plaquenil	68382009605

Rx code set	Code set description	ndc
RX-113	Sulfasalazine	00005396031
RX-113	Sulfasalazine	00013010101
RX-113	Sulfasalazine	00013010105
RX-113	Sulfasalazine	00013010111
RX-113	Sulfasalazine	00013010120
RX-113	Sulfasalazine	00013010201
RX-113	Sulfasalazine	00013010205
RX-113	Sulfasalazine	00013010220
RX-113	Sulfasalazine	00016010101
RX-113	Sulfasalazine	00016010105
RX-113	Sulfasalazine	00016010110
RX-113	Sulfasalazine	00016010111
RX-113	Sulfasalazine	00016010201
RX-113	Sulfasalazine	00016010205
RX-113	Sulfasalazine	00016010306
RX-113	Sulfasalazine	00032206001
RX-113	Sulfasalazine	00032206010
RX-113	Sulfasalazine	00032206011

RX-113	Sulfasalazine	00032208001
RX-113	Sulfasalazine	00032208010
RX-113	Sulfasalazine	00102275501
RX-113	Sulfasalazine	00150115240
RX-113	Sulfasalazine	00150115260
RX-113	Sulfasalazine	00150115280
RX-113	Sulfasalazine	00157069601
RX-113	Sulfasalazine	00157069605
RX-113	Sulfasalazine	00182101601
RX-113	Sulfasalazine	00182101605
RX-113	Sulfasalazine	00182101610
RX-113	Sulfasalazine	00223172701
RX-113	Sulfasalazine	00223172702
RX-113	Sulfasalazine	00223172705
RX-113	Sulfasalazine	00228239910
RX-113	Sulfasalazine	00228239950
RX-113	Sulfasalazine	00254590528
RX-113	Sulfasalazine	00302671001
RX-113	Sulfasalazine	00302671005
RX-113	Sulfasalazine	00302671201
RX-113	Sulfasalazine	00302671205
RX-113	Sulfasalazine	00304026900
RX-113	Sulfasalazine	00304026901
RX-113	Sulfasalazine	00304026905
RX-113	Sulfasalazine	00304117901
RX-113	Sulfasalazine	00306646185
RX-113	Sulfasalazine	00306647090
RX-113	Sulfasalazine	00349234900
RX-113	Sulfasalazine	00349234901
RX-113	Sulfasalazine	00349234905
RX-113	Sulfasalazine	00349234998
RX-113	Sulfasalazine	00349829201
RX-113	Sulfasalazine	00349829205
RX-113	Sulfasalazine	00359036710
RX-113	Sulfasalazine	00359037010
RX-113	Sulfasalazine	00359037040
RX-113	Sulfasalazine	00359037050
RX-113	Sulfasalazine	00364044401
RX-113	Sulfasalazine	00364044405
RX-113	Sulfasalazine	00364068801
RX-113	Sulfasalazine	00368102001
RX-113	Sulfasalazine	00405495601
RX-113	Sulfasalazine	00405495602
RX-113	Sulfasalazine	00440842091
RX-113	Sulfasalazine	00536461301
RX-113	Sulfasalazine	00536461305
RX-113	Sulfasalazine	00536461701
RX-113	Sulfasalazine	00536461705
RX-113	Sulfasalazine	00536461710
RX-113	Sulfasalazine	00537614801
RX-113	Sulfasalazine	00537614805
RX-113	Sulfasalazine	00537614810
RX-113	Sulfasalazine	00580033101
RX-113	Sulfasalazine	00580033105
RX-113	Sulfasalazine	00580146001
RX-113	Sulfasalazine	00580146005
RX-113	Sulfasalazine	00591079601
RX-113	Sulfasalazine	00591079605

RX-113	Sulfasalazine	00591079610
RX-113	Sulfasalazine	00591550301
RX-113	Sulfasalazine	00591550303
RX-113	Sulfasalazine	00591550304
RX-113	Sulfasalazine	00603580104
RX-113	Sulfasalazine	00603580121
RX-113	Sulfasalazine	00603580128
RX-113	Sulfasalazine	00603580132
RX-113	Sulfasalazine	00603580221
RX-113	Sulfasalazine	00603580228
RX-113	Sulfasalazine	00603580321
RX-113	Sulfasalazine	00603580325
RX-113	Sulfasalazine	00615152201
RX-113	Sulfasalazine	00615152205
RX-113	Sulfasalazine	00615152213
RX-113	Sulfasalazine	00615152253
RX-113	Sulfasalazine	00615152263
RX-113	Sulfasalazine	00615152265
RX-113	Sulfasalazine	00659010605
RX-113	Sulfasalazine	00677048301
RX-113	Sulfasalazine	00677048305
RX-113	Sulfasalazine	00686004420
RX-113	Sulfasalazine	00719192710
RX-113	Sulfasalazine	00719192810
RX-113	Sulfasalazine	00719192812
RX-113	Sulfasalazine	00719192813
RX-113	Sulfasalazine	00725005901
RX-113	Sulfasalazine	00725005904
RX-113	Sulfasalazine	00725005905
RX-113	Sulfasalazine	00725005910
RX-113	Sulfasalazine	00725013101
RX-113	Sulfasalazine	00725013105
RX-113	Sulfasalazine	00725013110
RX-113	Sulfasalazine	00779013101
RX-113	Sulfasalazine	00779102525
RX-113	Sulfasalazine	00779105225
RX-113	Sulfasalazine	00779105227
RX-113	Sulfasalazine	00781104501
RX-113	Sulfasalazine	00781104505
RX-113	Sulfasalazine	00814723014
RX-113	Sulfasalazine	00814723028
RX-113	Sulfasalazine	00814723114
RX-113	Sulfasalazine	00814723128
RX-113	Sulfasalazine	00839609806
RX-113	Sulfasalazine	00839609812
RX-113	Sulfasalazine	00839609816
RX-113	Sulfasalazine	00839674406
RX-113	Sulfasalazine	00839674412
RX-113	Sulfasalazine	00904115140
RX-113	Sulfasalazine	00904115160
RX-113	Sulfasalazine	00904115180
RX-113	Sulfasalazine	00904115240
RX-113	Sulfasalazine	00904115260
RX-113	Sulfasalazine	00904115261
RX-113	Sulfasalazine	00904115270
RX-113	Sulfasalazine	00904115280
RX-113	Sulfasalazine	00948515901
RX-113	Sulfasalazine	00948520201

RX-113	Sulfasalazine	01050115260
RX-113	Sulfasalazine	05364061305
RX-113	Sulfasalazine	10876046105
RX-113	Sulfasalazine	11289211905
RX-113	Sulfasalazine	11845012101
RX-113	Sulfasalazine	11845012103
RX-113	Sulfasalazine	12071034101
RX-113	Sulfasalazine	12071034105
RX-113	Sulfasalazine	12071034199
RX-113	Sulfasalazine	17022838002
RX-113	Sulfasalazine	17022838004
RX-113	Sulfasalazine	17236028501
RX-113	Sulfasalazine	17236028505
RX-113	Sulfasalazine	17236028510
RX-113	Sulfasalazine	17236029101
RX-113	Sulfasalazine	17236029105
RX-113	Sulfasalazine	23490631300
RX-113	Sulfasalazine	35470005901
RX-113	Sulfasalazine	35470005905
RX-113	Sulfasalazine	35470008705
RX-113	Sulfasalazine	35470024801
RX-113	Sulfasalazine	38022032801
RX-113	Sulfasalazine	43353049553
RX-113	Sulfasalazine	43353049570
RX-113	Sulfasalazine	43353049580
RX-113	Sulfasalazine	45124007801
RX-113	Sulfasalazine	45124007805
RX-113	Sulfasalazine	45124007810
RX-113	Sulfasalazine	46198023101
RX-113	Sulfasalazine	46198023105
RX-113	Sulfasalazine	47202237101
RX-113	Sulfasalazine	47202237102
RX-113	Sulfasalazine	47202271001
RX-113	Sulfasalazine	49648026900
RX-113	Sulfasalazine	49648026901
RX-113	Sulfasalazine	49648026905
RX-113	Sulfasalazine	49648117901
RX-113	Sulfasalazine	49727004204
RX-113	Sulfasalazine	49999098100
RX-113	Sulfasalazine	50430004003
RX-113	Sulfasalazine	50430004005
RX-113	Sulfasalazine	50430004006
RX-113	Sulfasalazine	51079004420
RX-113	Sulfasalazine	51079004440
RX-113	Sulfasalazine	51079004450
RX-113	Sulfasalazine	51079015540
RX-113	Sulfasalazine	51079015550
RX-113	Sulfasalazine	51382010701
RX-113	Sulfasalazine	51382010705
RX-113	Sulfasalazine	51432044103
RX-113	Sulfasalazine	51432044105
RX-113	Sulfasalazine	51432044200
RX-113	Sulfasalazine	51432044203
RX-113	Sulfasalazine	51432044205
RX-113	Sulfasalazine	51655011177
RX-113	Sulfasalazine	51728004601
RX-113	Sulfasalazine	51728004605
RX-113	Sulfasalazine	51728064801

RX-113	Sulfasalazine	51728064805
RX-113	Sulfasalazine	52446044421
RX-113	Sulfasalazine	52446044428
RX-113	Sulfasalazine	52446044621
RX-113	Sulfasalazine	52544079601
RX-113	Sulfasalazine	52544079605
RX-113	Sulfasalazine	52544079610
RX-113	Sulfasalazine	52728028510
RX-113	Sulfasalazine	53002029700
RX-113	Sulfasalazine	53258017213
RX-113	Sulfasalazine	53489014701
RX-113	Sulfasalazine	53489014705
RX-113	Sulfasalazine	53489014710
RX-113	Sulfasalazine	54274000410
RX-113	Sulfasalazine	54274000430
RX-113	Sulfasalazine	54274005210
RX-113	Sulfasalazine	54274005230
RX-113	Sulfasalazine	54569007200
RX-113	Sulfasalazine	54569007201
RX-113	Sulfasalazine	54569007227
RX-113	Sulfasalazine	54569007250
RX-113	Sulfasalazine	54569031300
RX-113	Sulfasalazine	54569031301
RX-113	Sulfasalazine	54569031302
RX-113	Sulfasalazine	54569031303
RX-113	Sulfasalazine	54868112301
RX-113	Sulfasalazine	54868113800
RX-113	Sulfasalazine	54868113801
RX-113	Sulfasalazine	54868113803
RX-113	Sulfasalazine	54868113804
RX-113	Sulfasalazine	54868113805
RX-113	Sulfasalazine	54868113806
RX-113	Sulfasalazine	54868113900
RX-113	Sulfasalazine	55081050100
RX-113	Sulfasalazine	55081050101
RX-113	Sulfasalazine	55289017610
RX-113	Sulfasalazine	55289017640
RX-113	Sulfasalazine	56126030611
RX-113	Sulfasalazine	57362046184
RX-113	Sulfasalazine	58016007400
RX-113	Sulfasalazine	58016007430
RX-113	Sulfasalazine	58016007460
RX-113	Sulfasalazine	58016007490
RX-113	Sulfasalazine	59762010401
RX-113	Sulfasalazine	59762010402
RX-113	Sulfasalazine	59762010414
RX-113	Sulfasalazine	59762500001
RX-113	Sulfasalazine	59762500002
RX-113	Sulfasalazine	60346081240
RX-113	Sulfasalazine	60346081294
RX-113	Sulfasalazine	61392014730
RX-113	Sulfasalazine	61392014731
RX-113	Sulfasalazine	61392014732
RX-113	Sulfasalazine	61392014739
RX-113	Sulfasalazine	61392014745
RX-113	Sulfasalazine	61392014751
RX-113	Sulfasalazine	61392014754
RX-113	Sulfasalazine	61392014760

RX-113	Sulfasalazine	61392014790
RX-113	Sulfasalazine	61392014791
RX-113	Sulfasalazine	68258908601

Rx code set	Code set description	ndc
RX-233	Abatacept	00003218710

Rx code set	Code set description	ndc
RX-234	Rituximab	50242005121
RX-234	Rituximab	50242005306

2a.9 Denominator Exclusions (*Brief text description of exclusions from the target population***):** Does not apply

2a.10 Denominator Exclusion Details (*All information required to collect exclusions to the denominator, including all codes, logic, and definitions***):**
Does not apply

2a.11 Stratification Details/Variables (*All information required to stratify the measure including the stratification variables, all codes, logic, and definitions***):**

2a.12-13 Risk Adjustment Type: no risk adjustment necessary

2a.14 Risk Adjustment Methodology/Variables (*List risk adjustment variables and describe conceptual models, statistical models, or other aspects of model or method***):**

2a.15-17 Detailed risk model available Web page URL or attachment:

2a.18-19 Type of Score: rate/proportion
2a.20 Interpretation of Score: better quality = higher score
2a.21 Calculation Algorithm (*Describe the calculation of the measure as a flowchart or series of steps***):**
1. Exclude members who meet denominator exclusion criteria
2. Assign a YES or NO result to remaining members based on numerator response
3. Rate = YES/[YES+NO]

2a.22 Describe the method for discriminating performance *(e.g., significance testing)***:**
Over 8200 patients met the denominator from a geographically diverse 15 million member benchmark database. More than 2700 patients did not meet numerator compliance, indicating a significant population with patient safety gap in care. The subsequent compliance rate was 66.6 percent.

2a.23 Sampling (Survey) Methodology *If measure is based on a sample (or survey), provide instructions for obtaining the sample, conducting the survey and guidance on minimum sample size (response rate)*:
A 15 million patient population sample was chosen to analyze the potential patient safety gap in care. The sample was derived from more than 60 million patients based on criteria including national geographic representation, commercial health coverage and patient age less than 65.

2a.24 Data Source (*Check the source(s) for which the measure is specified and tested)***:**
Electronic clinical data, pharmacy data, lab data

2a.25 Data source/data collection instrument (*Identify the specific data source/data collection instrument, e.g. name of database, clinical registry, collection instrument, etc.***):**
Our data source is a proprietary Ingenix provider database that includes more than 60 million patients, over multiple years. It includes data from multiple payors. This measure specifically uses the following data from this database: member demographics, ICD-9 codes, revenue codes, CPT codes, place of service codes, and pharmacy claims.

2a.26-28 Data source/data collection instrument reference web page URL or attachment:

2a.29-31 Data dictionary/code table web page URL or attachment: Attachment Input Guide_NQF-634001965105525603.doc

2a.32-35 Level of Measurement/Analysis (*Check the level(s) for which the measure is specified and tested)*
Clinicians: Individual, Clinicians: Group, Population: states, Population: counties or cities, Program: Disease management, Program: QIO, Facility/Agency, Health Plan, Integrated delivery system, Multi-site/corporate chain, Can be measured at all levels

2a.36-37 Care Settings (*Check the setting(s) for which the measure is specified and tested)*
Ambulatory Care: Clinic, Ambulatory Care: Emergency Dept, Ambulatory Care: Hospital Outpatient, nursing home (NH) /Skilled Nursing Facility (SNF), Rehabilitation Facility

2a.38-41 Clinical Services (*Healthcare services being measured, check all that apply*)
Clinicians: PA/NP/Advanced Practice Nurse, Clinicians: Physicians (MD/DO)

TESTING/ANALYSIS

2b. Reliability testing

2b.1 Data/sample *(description of data/sample and size)***:** Reliability is tested by using multiple databases. There are three primary databases that we use: 1) a customer acceptance (CAT) database that includes approximately 4000 members who satisfy the condition confirmation criteria; 2) a one million member face validity testing (FVT) database that is geographically diverse; and 3) a 15 million member benchmark database that is geographically diverse. All databases represent predominately a commercial population less than 65 year of age.

2b.2 Analytic Method *(type of reliability & rationale, method for testing)***:**
Quality assurance of each measure is accomplished through the testing using multiple methods and databases. Types of testing, data samples and volume vary to ensure the integrity of the measure. Rigorous development, analysis and testing processes are deployed for creating measure specifications. Software testing ensures the software is working as designed. Reliability and validity testing of measures is based on differing data samples and volume of members. National benchmarks are created on a large volume set of data representing members throughout the United States. All quality checks for all measure results must have consistent results and meet expected outcomes based on industry knowledge and experience.

Customer Acceptance Testing (CAT) is an important quality process. CAT ensures that the clinical measures are functioning as intended and that they generate accurate results for typical billing patterns. Using actual claims data a team of business analysts, nurses, and health services researchers conducts a detailed analysis of the output. For each clinical condition in the product (e.g., Diabetes Mellitus, Coronary Artery Disease, etc.) there is a set of CAT data with at least 4000 members who satisfy the condition confirmation criteria. This data is extracted from a large (50+ million member) multi-payer benchmark database and contains inpatient, outpatient, pharmacy, and laboratory data. The testing team analyzes claims from individual members and compares the creation of denominators (target population), numerators, and exclusions from this manual review process to output results from the quality measure.

Regression testing is the part of CAT that verifies the reliability of the product across software releases. For a new release the testing team confirms that every unchanged measure produces the same results as in previous releases, accounting for systematic changes to the software (e.g., code updates, logic changes, etc). Regression testing is conducted at multiple points throughout the software development cycle.

2b.3 Testing Results *(reliability statistics, assessment of adequacy in the context of norms for the test conducted)***:**
Given the size of our benchmark database, it is the most reliable source for compliance results. Over 8200 members from the benchmark database met the denominator definition for this measure. The overall compliance rate was 66.6 percent.

2b
C☐
P☐
M☐
N☐

2c. Validity testing

2c.1 Data/sample *(description of data/sample and size)*: Our data sample for face validity testing includes a geographically diverse one million member database. Our data sample for benchmark testing includes a geographically diverse 15 million member database. Both databases represent predominately a commercial population less than 65 year of age.

2c.2 Analytic Method *(type of validity & rationale, method for testing)*:
Face Validity Testing (FVT) is the final testing step in the software release cycle. One million members are randomly selected from the large multi-payer benchmark database and their claims data is processed through the software. The Medical Director reviews the results to verify that:
1. Prevalence rates for a condition are comparable to nationally published rates
2. Compliance rates for a measure are comparable to the rates reported in the published literature or by other national sources (e.g. HEDIS). If no comparable sources are available, the rates are judged based on what is clinically reasonable.
In addition, all results are reviewed for face validity by members of an external physician clinical consultant panel.

A similar review of benchmark test results occurs in conjunction with a software release. With benchmark testing, 15 million members are randomly selected from the large multi-payer benchmark database and their claims data is processed through the software.

Our claims-based measures have been validated using a chart review comparison process. This validation project is summarized below:
Goal: evaluate the reliability of claims-based measure results using chart review as the gold standard
Methods:
The charts of 100 members from two clinics in one city were reviewed. Results from our claims-based measures were compared to information present in the chart. During this process, 726 measures were evaluated.
Results:
The overall error rate was less than 5%. The error rate varied depending on the type of claim required for numerator compliance and is summarized as follows:
o The error rate was highest with medications, with an 11 percent error rate (2/18). From chart review, it was difficult to tell if this represented a real error, a medication sample was provided, or the prescription was never filled).
o The error rate was 4 percent (14/318) for measures that required labs for numerator compliance. It was noted that a claims-based measure approach sometimes identified labs that were missing in chart review.
o The error rate for office visit and specialty appointments was 2 percent (8/390). Of note, administrative claims was more likely than chart review to identify relevant office and specialty visits, particularly for appointments that occurred outside the clinic or network.
o Errors were found related to coding in claims data, not due to the claims-based measures or methodology. These errors were not quantified.

2c.3 Testing Results *(statistical results, assessment of adequacy in the context of norms for the test conducted)*:
Summarized in 2b3

2c
C☐
P☐
M☐
N☐

2d. Exclusions Justified

2d.1 Summary of Evidence supporting exclusion(s):
This measure does not include any exclusions.

2d.2 Citations for Evidence:

2d.3 Data/sample *(description of data/sample and size)*:

2d.4 Analytic Method *(type analysis & rationale)*:

2d
C☐
P☐
M☐
N☐
NA☐

2d.5 **Testing Results** *(e.g., frequency, variability, sensitivity analyses)*:	
2e. Risk Adjustment for Outcomes/ Resource Use Measures 2e.1 **Data/sample** *(description of data/sample and size)*: This measure does not include risk adjustment. 2e.2 **Analytic Method** *(type of risk adjustment, analysis, & rationale)*: 2e.3 **Testing Results** *(risk model performance metrics)*: 2e.4 **If outcome or resource use measure is not risk adjusted, provide rationale:**	**2e** C☐ P☐ M☐ N☐ NA☐
2f. Identification of Meaningful Differences in Performance 2f.1 **Data/sample from Testing or Current Use** *(description of data/sample and size)*: Our benchmark data sample includes a geographically diverse 15 million member benchmark database. The database represents predominately a commercial population less than 65 year of age. 2f.2 **Methods to identify statistically significant and practically/meaningfully differences in performance** *(type of analysis & rationale)*: During benchmark testing, 15 million members are randomly selected from the large multi-payer benchmark database and their claims data is processed through the software. The Medical Director reviews the results to verify that: 1. Prevalence rates for a condition are comparable to nationally published rates 2. Compliance rates for a measure are comparable to the rates reported in the published literature or by other national sources (e.g. HEDIS). If no comparable sources are available, the rates are judged based on what is clinically reasonable. In addition, all results are systematically reviewed for face validity by members of an external physician clinical consultant panel. 2f.3 **Provide Measure Scores from Testing or Current Use** *(description of scores, e.g., distribution by quartile, mean, median, SD, etc.; identification of statistically significant and meaningfully differences in performance)*: Summarized in 2b3	**2f** C☐ P☐ M☐ N☐
2g. Comparability of Multiple Data Sources/Methods 2g.1 **Data/sample** *(description of data/sample and size)*: 2g.2 **Analytic Method** *(type of analysis & rationale)*: 2g.3 **Testing Results** *(e.g., correlation statistics, comparison of rankings)*:	**2g** C☐ P☐ M☐ N☐ NA☐
2h. Disparities in Care 2h.**1 If measure is stratified, provide stratified results** *(scores by stratified categories/cohorts)*: 2h.2 **If disparities have been reported/identified, but measure is not specified to detect disparities, provide follow-up plans:**	**2h** C☐ P☐ M☐ N☐ NA☐
TAP/Workgroup: What are the strengths and weaknesses in relation to the sub-criteria **for** *Scientific*	**2**

Acceptability of Measure Properties?	
Steering Committee: Overall, to what extent was the criterion, *Scientific Acceptability of Measure Properties*, **met?** **Rationale:**	*2* **C☐** **P☐** **M☐** **N☐**
3. USABILITY	
Extent to which intended audiences (e.g., consumers, purchasers, providers, policy makers) can understand the results of the measure and are likely to find them useful for decision making. (evaluation criteria)	Eval Rating
3a. Meaningful, Understandable, and Useful Information 3a.1 **Current Use:** in use 3a.2 **Use in a public reporting initiative (disclosure of performance results to the public at large)** (*If used in a public reporting initiative, provide name of initiative(s), locations, Web page URL(s). If not publicly reported, state the plans to achieve public reporting within 3 years*)**:** Health plans, physicians (individuals and groups), care management, and other vendors/customers are using this measure on a national level. However, we do not know if this specific measure is being used as part of a public reporting initiative. 3a.3 **If used in other programs/initiatives (***If used in quality improvement or other programs/initiatives, name of initiative(s), locations, Web page URL(s). If not used for QI, state the plans to achieve use for QI within 3 years***):** Health plans, physicians (individuals and groups), care management, and other vendors/customers use many of our measures on a national level for quality improvement, disease management, and physician sharing programs. Customers are able to select their measures depending on their business needs. As such, we do not know which specific measures are used by our customers. **Testing of Interpretability** (*Testing that demonstrates the results are understood by the potential users for public reporting and quality improvement*) 3a.4 **Data/sample** *(description of data/sample and size)***:** Results are summarized and reported by users/customers depending on their business need - we do not have access to this information. Because of us my multiple users/customers, there is no single data sample, methodology, or public reporting format. 3a.5 **Methods** *(e.g., focus group, survey, QI project)***:** 3a.6 **Results** *(qualitative and/or quantitative results and conclusions)***:**	**3a** **C☐** **P☐** **M☐** **N☐**
3b/3c. Relation to other NQF-endorsed measures 3b.1 **NQF # and Title of similar or related measures:**	
(for NQF staff use) **Notes on similar/related** endorsed **or submitted measures:**	
3b. Harmonization If this measure is related to measure(s) already endorsed by NQF (e.g., same topic, but different target population/setting/data source or different topic but same target population): 3b.2 **Are the measure specifications harmonized? If not, why?**	**3b** **C☐** **P☐** **M☐** **N☐** **NA☐**
3c. Distinctive or Additive Value 3c.1 **Describe the distinctive, improved, or additive value this measure provides to existing NQF-endorsed measures:**	**3c** **C☐** **P☐** **M☐** **N☐**

5.1 Competing Measures If this measure is similar to measure(s) already endorsed by NQF (i.e., on the same topic and the same target population), describe why it is a more valid or efficient way to measure quality:	
TAP/Workgroup: What are the strengths and weaknesses in relation to the sub-criteria **for** *Usability?*	**3**
Steering Committee: Overall, to what extent was the criterion, *Usability*, **met?** **Rationale:**	**3** **C☐** **P☐** **M☐** **N☐**
4. FEASIBILITY	
Extent to which the required data are readily available, retrievable without undue burden, and can be implemented for performance measurement. (evaluation criteria)	Eval Rating
4a. Data Generated as a Byproduct of Care Processes **4a.1-2 How are the data elements that are needed to compute measure scores generated?** coding/abstraction performed by someone other than person obtaining original information,	**4a** **C☐** **P☐** **M☐** **N☐**
4b. Electronic Sources **4b.1 Are all the data elements available electronically?** (*elements that are needed to compute measure scores are in defined, computer-readable fields, e.g., electronic health record, electronic claims*) Yes **4b.2 If not, specify the near-term path to achieve electronic capture by most providers.**	**4b** **C☐** **P☐** **M☐** **N☐**
4c. Exclusions **4c.1 Do the specified exclusions require additional data sources beyond what is required for the numerator and denominator specifications?** No **4c.2 If yes, provide justification.**	**4c** **C☐** **P☐** **M☐** **N☐** **NA☐**
4d. Susceptibility to Inaccuracies, Errors, or Unintended Consequences **4d.1 Identify susceptibility to inaccuracies, errors, or unintended consequences of the measure and describe how these potential problems could be audited. If audited, provide results.** It is possible that some CBC claims could be missed if obtained during a hospitalization. However, the guideline recommendation is for CBC testing every 4-12 weeks at minimum depending on the DMARD and numerator compliance for our measure will be met if at least one test was done during the last 3 months of the report period through 90 days after the report period (a 6 month total time period). We believe that our 6 month timeframe minimizes the likelihood that this error would impact the compliance results.	**4d** **C☐** **P☐** **M☐** **N☐**
4e. Data Collection Strategy/Implementation **4e.1 Describe what you have learned/modified as a result of testing and/or operational use of the measure regarding data collection, availability of data/missing data, timing/frequency of data collection, patient confidentiality, time/cost of data collection, other feasibility/ implementation issues:** No modifications have been made based on testing or operational use of the measure. **4e.2 Costs to implement the measure** (*costs of data collection, fees associated with proprietary*	**4e** **C☐** **P☐** **M☐** **N☐**

measures): We do not have access to this information. This would vary based on the customer/vendor, patient population, and programs/interventions associated with measure use. 4e.3 **Evidence for costs:** 4e.4 **Business case documentation:**	
TAP/Workgroup: What are the strengths and weaknesses in relation to the sub-criteria **for** *Feasibility*?	**4**
Steering Committee: Overall, to what extent was the criterion, *Feasibility*, **met?** **Rationale:**	**4** **C☐** **P☐** **M☐** **N☐**
RECOMMENDATION	
(for NQF staff use) **Check if measure is untested and only eligible for time-limited endorsement.**	**Time-limited ☐**
Steering Committee: Do you recommend for endorsement? **Comments:**	**Y☐** **N☐** **A☐**

CONTACT INFORMATION

Co.1 **Measure Steward (Intellectual Property Owner)**
Co.1 **Organization**
Ingenix | 12125 Technology Drive | Eden Prairie | Minnesota | 55344

Co.2 **Point of Contact**
Kay | Schwebke, Medical Director | kay.schwebke@ingenix.com | 952-833-7154

Measure Developer If different from Measure Steward
Co.3 **Organization**
Ingenix | 12125 Technology Drive | Eden Prairie | Minnesota | 55344

Co.4 **Point of Contact**
Kay | Schwebke, Medical Director | kay.schwebke@ingenix.com | 952-833-7154

Co.5 **Submitter If different from Measure Steward POC**
Kay | Schwebke, Medical Director | kay.schwebke@ingenix.com | 952-833-7154- |Ingenix

Co.6 **Additional organizations that sponsored/participated in measure development**
This measure has been reviewed and supported by the American Academy of Family Physicians.

ADDITIONAL INFORMATION

Workgroup/Expert Panel involved in measure development
Ad.1 **Provide a list of sponsoring organizations and workgroup/panel members' names and organizations. Describe the members' role in measure development.**
We have an external consultant panel that participates in the original literature search process, measure development, code set review, testing review, and maintenance processes. Panel members include the following:

NAME & Title Employer/Position
Alexander, Beth Pharm D, BCPS Assistant Professor, Augsburg College
Ayenew, Woubeshet, MD Hennepin Faculty Associates; Hennepin County Medical Center
Becker, Keith, MD Fairview Medical Center
Betcher, Susan, MD Allina Medical Clinic

Bruer, Paul, MD Comprehensive Ophthamology, LLC
Capecchi, Joseph, MD Allina Medical Clinic
Giesler, Janell, MD Allina Medical Clinic
Grabowski, Carol, MD Allina Medical Clinic
Hansen, Calvin, MD Iowa Health Physicians
Hargrove, Jody, MD Arthritis and Rheumatology Consultants
Hermann, Richard, MD Tufts - New England Medical Center
Jemming, Brian, Pharm D CentraCare Health System
Kohen, Jeffrey, MD Veterans Affairs Medical Center
McCarthy, Teresa, MD University of Minnesota, Department of Family Medicine & Community Health
McEvoy, Charlene, MD, MPH HealthPartners & HealthPartners Research Foundation; Assistant Professor of Medicine, University of Minnesota
McGee, Deanna, Pharm D, BCPS Retail Pharmacy
Ogle, Kathleen, MD Hennepin Faculty Associates; Hennepin County Medical Center: Assistant Professor of Medicine, University of Minnesota Medical School
Peter, Kathleen, MD Park Nicollet Medical Center
Pieper-Bigelow, Christina, MD Allina Medical Clinic
Redmon, Bruce, MD University of Minnesota Physicians
Scharpf, Steven, MD Mountain Valleys Health Centers
Weitz, Carol, MD Independent

Ad.2 If adapted, provide name of original measure:
Ad.3-5 If adapted, provide original specifications URL or attachment

Measure Developer/Steward Updates and Ongoing Maintenance
Ad.6 Year the measure was first released: 2006
Ad.7 Month and Year of most recent revision: 2009-12
Ad.8 What is your frequency for review/update of this measure? every three years at minimum
Ad.9 When is the next scheduled review/update for this measure? 2012-12

Ad.11 -13 Additional Information web page URL or attachment:

Date of Submission (*MM/DD/YY*)**:** 01/27/2010

INGENIX®

Input Guide

Release 7.0, Technical Guide for Windows, February 2008

Ingenix
950 Winter Street, Suite 3800
Waltham, MA 02451
Customer Support:
Tel: 866.818.7424
Fax: 781.895.9951
SymmetrySuite.Support@ingenix.com

What Input Files to Prepare

The following list specifies what input files you prepare for processing:

- The claims data file (required)
- The member data file (required)
- The member term data file (required)

Field Type Definitions and Input File Requirements

This chapter lists the field requirements for your input files. One of the attributes listed among the requirements is defined as "Type". There are four field types used to describe a field's value, and they are defined below.

Field Type	Definition
AlphaNum	A value made of letters and/or numbers. If a value of this type is made of numbers only, it will not be a value that can be operated on mathematically. For example, it would be inappropriate to subtract one procedure code from another procedure code even though both values may contain only numbers.
Num	A value made of numbers only, and which can logically be operated on mathematically. Age is an example of this type. One particular field, while not used in mathematical calculations, is defined in the EBM Connect software as such that it accepts only numeric values. (To enter a non-numeric value would cause EBM Connect processing to stop.) Therefore, this field is defined as Num. It is the Case ID field in the optional disease registry input file.
Date	A value which can be interpreted as a date value. Values should always use four-digit years but the format may vary otherwise.
DecNum	A value made of numbers and a decimal point. These values can also logically be operated on mathematically.

Claims Input File

The claims file contains detailed information on services that were billed or performed or otherwise rendered. The claims file includes:

- Medical claims, including medical services, facility services and clinic services
- Pharmacy claims, including billed prescriptions and drugs
- Lab claims, including lab test and results information

Field Name	Type	Length	Required or Optional
Family ID	AlphaNum	1-30	Always required for all claims
Patient ID	AlphaNum	0-2	Optional
Amount Paid	DecNum	1-11	Required for all claims
Amount Allowed	DecNum	0-11	Required for all claims
Procedure Code	AlphaNum	5	Required if there is no revenue code, NDC, or LOINC® code
Procedure Code Modifier	AlphaNum	2	Required for medical claims
Revenue Code	AlphaNum	0 or 4	Optional (applies to medical claims when used)
First Diagnosis Code	AlphaNum	5 or 6	Required for medical claims
Second Diagnosis Code	AlphaNum	0, 5 or 6	Optional (applies to medical claims when used)
Third Diagnosis Code	AlphaNum	0, 5 or 6	Optional (applies to medical claims when used)
Fourth Diagnosis Code	AlphaNum	0, 5 or 6	Optional (applies to medical claims when used)
First Date of Service	Date	8 or 10	Always required for all claims
Last Date of Service	Date	8 or 10	Required for all claims

Paid Date	Date	0, 8 or 10	Optional
Type of Service	AlphaNum	0-10	Optional
Provider ID	AlphaNum	1-20	Required for medical claims
Ordering Provider ID	AlphaNum	0-20	Optional
Provider Type	AlphaNum	1-10	Required for medical claims
Provider Specialty Type	AlphaNum	1-10	Required for medical claims
Provider Key	AlphaNum	1-20	Required for medical claims
NDC	AlphaNum	0 or 11	Required for Rx claims
Day Supply	Num	0-4	Required for Rx claims
Quantity Count	DecNum	0-10	Required for Rx claims
LOINC®	AlphaNum	0 or 7	Required for lab claims
Lab Test Result	AlphaNum	0-18	Required for lab claims
Place of Service	AlphaNum	1-10	Required for medical claims
Unique Record ID	AlphaNum	1-28	Required for all claims
Claim Number	AlphaNum	1-28	Required for all claims
Bill Type Frequency Indicator	Num	0 or 1	Optional
Patient Status	AlphaNum	1-2	Required for facility claims (involving admission or confinement).
Facility Type	AlphaNum	0-2	Optional
Bed Type	AlphaNum	0-1	Optional
First ICD-9 Procedure Code	AlphaNum	0, 4 or 5	Optional, but will impact results (applies to medical claims when used)
Second ICD-9 Procedure Code	AlphaNum	0, 4 or 5	Optional (see above)
Third ICD-9 Procedure Code	AlphaNum	0, 4 or 5	Optional (see above)
Fourth ICD-9 Procedure Code	AlphaNum	0, 4 or 5	Optional (see above)

Field Descriptions

Instructions for each input field are as follows:

Family ID

This field identifies all members of a family and can be any alphanumeric string.

Note: Remember that each Family ID (and Patient ID) listed in your claims input file must have a corresponding record in your member input data file and your member term data file.

Patient ID

This field identifies individual members within a family. If present, this field must be sorted within Family ID, so that all records for an individual are contiguous. If the Family ID uniquely identifies an individual, this field need not be specified (that is, its length in the dictionary will be zero).

Amount Paid

The amount paid for this claim line.

Amount Allowed

The allowed amount for this claim line. This amount typically represents the total amount reimbursed including deductibles, copays, coinsurance, insurer paid, etc.

Procedure Code

The procedure code must be one of:

- A procedure code specified in the Physician's Current Procedure Terminology, 4th Edition (CPT®-4 codes) defined by the American Medical Association, for the years 1997 and later.
- A procedure code specified by the HCFA Common Procedure Coding System, Level II code (HCPCS) defined by the Centers for Medicare and Medicaid Services (CMS) for the years 1999 and later.
- A National Uniform Billing Committee (NUBC) revenue code.

Note: When the NUBC code is entered in the Procedure Code field, it should be padded to the right with blanks because the Procedure Code field always occupies five characters.

- If your organization defines its own procedure codes and/or revenue codes, they must be mapped to standard procedure and revenue codes.

Procedure Code Modifier

Use this field to specify any procedure code modifier that accompanies the procedure code.

Revenue Code

The revenue code, if one was entered for the claim. Supported values in this field are NUBC revenue codes. If your organization defines its own revenue codes, they must be mapped to standard revenue codes.

The revenue code is an optional field, allowing you to define your input records so that you can place an NUBC revenue code and a CPT/HCPCS procedure code on a single record line.

For claim records that do not have a revenue code, leave the revenue code field blank.

First Diagnosis Code Through Fourth Diagnosis Code

Up to four diagnoses may be entered for each claim, but only the first is required.

If your organization defines its own diagnosis codes, they must be mapped to standard ICD-9 diagnosis codes.

First Date of Service and Last Date of Service

The first date and last date represented by the claim line. If you choose to use a date format with separators (such as YYYY/MM/DD or YYYY-MM-DD), the separators are ignored on input, so you can use any character as a separator. Valid formats include: YYYYMMDD, MMDDYYYY, DDMMYYYY, YYYY/MM/DD, MM/DD/ YYYY, and DD/MM/YYYY, where the separator can be any character.

Paid Date

This field is optional. This is the date the claim was paid. The format of the paid date must be the same as that used in the First and Last Date of Service.

Type of Service

This is an optional code which represents the type of service (TOS) performed for this claim. If no specific value is available for this field, it should be filled with blanks. If this field is not used (i.e., its length is set to zero in the configuration), non-pharmaceutical claims with no procedure code will be treated as ancillary records.

Provider ID

Provider identification number from the claim. Used to identify who performed the service.

Ordering Provider ID

This is an optional field. This is the identification number of the provider who ordered the service.

Provider Type

This code represents the type of provider who performed the service. Examples of provider types would be chiropractor, nurse practitioner, medical doctor, counselor, pharmacy, hospital or treatment facility.

Provider Specialty Type

This code represents the specialty of the provider who performed the service.

Provider Key

Unique number or code for a physician who has multiple provider IDs or specialties. A single health care provider may have multiple provider IDs in your input claims data, but this person or entity should have only one provider key.

NDC

If this is a pharmaceutical claim, this field should contain the drug's NDC code. For non-pharmaceutical claim records, the NDC field should be filled with blanks.

Day Supply

For pharmacy records, the number of days a filled prescription is expected to last. If you have no pharmacy records, the Days Supply is an optional field.

Quantity Count

Quantity of drug dispensed in metric units:

Each - solid oral dosage forms (tablet, capsule), powder filled (dry) vials, packets, patches, units of use packages, suppositories, bars.

Milliliter - (cc) liquid oral dosage forms, liquid filled vials, ampules, reconstituted oral products.

Grams - ointments, bulk powders (not IV).
If you have no pharmacy records, the Quantity Count is an optional field.

LOINC®

Logical Observation Identifiers Names and Codes (LOINC®). The LOINC Code is a universal identifier for a lab test for a particular analyte. The LOINC User's Guide and database can be found at www.regenstrief.org.

Enter a LOINC code if the record is a lab record. For non-lab records, leave the LOINC field blank.

If you have no lab records in your claims input, the LOINC code is optional.

Notes:

(1) When using lab results data that has not been mapped to a LOINC code, map the comparable vendor-specific test number provided by the laboratory vendor(s) to one of these default codes.

(2) This is a retired code which may be present on historical data, or which some laboratories may be continuing to use. Input record data with this code is included in the definition of this test.

Lab Test Result

If the record is a lab record, use this field to enter the result value of lab test. For non-lab records, this field should be blank.

If you have no lab records in your claims input, the Lab Test Result is optional.

Place of Service

Place of service (POS). You must map your internal POS codes to Centers for Medicare and Medicaid Services (CMS) standard POS codes.

Unique Record ID

This required field contains a unique identifier representing the service line from the claim. For medical services, this ID typically represents the service row from the CMS 1500 or CMS 1450/UB92 claim form.

Claim Number

A unique identifier used to link service lines for a specific claim submitted for a member. If a claim has multiple service lines, each service will have a unique record ID and the same claim number to represent the claim.

Bill Type Frequency Indicator

This optional field is used to indicate the disposition of confinements.

Patient Status

This field is required for facility claims. The contents will be the patient status indicator field from the NUBC UB-92 form. This field can denote whether the member died during a confinement.

Facility Type

This field is optional. Space for it is provided to allow for additional post grouping analysis. The contents will typically be the UB-92 facility type data value. This would allow records to be easily selected for diagnosis related grouping (DRG) based on the facility type.

Bed Type

If a value is present, this field acts as an additional discriminator in determining whether a Facility record extends an existing confinement or starts a new confinement.

First ICD-9 Procedure Code Through Fourth ICD-9 Procedure Code

If your claims have ICD-9 procedure codes, include them in your claims input file.

If a decimal point will appear in this field in your claim records, the length should be given as 5. If the decimal separator is not used, the length is 4. If these fields are unused, the length is zero.

Member Input File

The member data file contains the most current information about the member.

Field Descriptions

Field	Type	Length	Required or Optional
Family ID	AlphaNum	1-30	Required
Patient ID	AlphaNum	0-2	Optional
Patient Gender	AlphaNum	1	Required
Date of Birth	Date	8 or 10	Required
Member Beginning Eligibility Date	Date	0, 8 or 10	Optional
Member Ending Eligibility Date	Date	0, 8 or 10	Optional

Instructions for each input field are as follows:

Family ID

This field identifies all members of a family and can be any alphanumeric string. The records in the member file must be sorted first on the Family ID (together with Patient ID, if available) so that all records for an individual are contiguous.

Patient ID

This field identifies individual members within a family. If present, this field must be sorted within Family ID, so that all records for an individual are contiguous. If the Family ID uniquely identifies an individual, this field need not be specified (that is, its length in the dictionary will be zero).

Patient Gender and Date of Birth

The member's gender (F or M) and date of birth. If you choose to use a date format with separators (such as YYYY/MM/DD or YYYY-MM-DD), the separators are ignored on input, so you can use any character as a separator. Valid date formats include: YYYYMMDD, MMDDYYYY, DDMMYYYY, YYYY/MM/DD, MM/DD/YYYY, and DD/MM/YYYY, where the separator can be any character.

Member Beginning Eligibility Date and Ending Eligibility Date

The first date on which the member became covered under the plan and the last date of the member's coverage. If you choose to use a date format with separators (such as YYYY/MM/DD or YYYY-MM-DD), the separators are ignored on input, so you can use any character as a separator. Valid formats include: YYYYMMDD, MMDDYYYY, DDMMYYYY, YYYY/MM/DD, MM/DD/YYYY, and DD/MM/YYYY, where the separator can be any character.

Member Term Input File

The member term data file contains member coverage and term activity information. Plan coverage begin and end dates are required in order to correctly calculate the other fields in the member term file. There may be more than one record per individual member.

Field Descriptions

Field	Type	Length	Required or Optional
Family ID	AlphaNum	1-30	Required
Patient ID	AlphaNum	0-2	Optional
Member Beginning Eligibility Date	Date	8 or 10	Required
Member Ending Eligibility Date	Date	8 or 10	Required
Primary Care Provider	AlphaNum	20	Required
Provider Specialty Type	AlphaNum	1-10	Required
Medical Flag	AlphaNum	1	Required
Pharmacy Flag	AlphaNum	1	Required

Instructions for each input field are as follows:

Family ID

This field identifies all members of a family and can be any alphanumeric string. The records in the member term file must be sorted first on the Family ID (together with Patient ID, if available) so that all records for an individual are contiguous.

Patient ID

This field identifies individual members within a family.

Member Beginning Eligibility Date and Member Ending Eligibility Date

The first date on which the member became covered under the plan and the last date of the member's coverage. If you choose to use a date format with separators (such as YYYY/MM/DD or YYYY-MM-DD), the separators are ignored on input, so you can use any character as a separator. Valid formats include: YYYYMMDD, MMDDYYYY, DDMMYYYY, YYYY/MM/DD, MM/DD/YYYY, and DD/MM/YYYY, where the separator can be any character.

Primary Care Provider

The provider key for the member's primary care physician. A single health care physician may have multiple provider IDs in your input claims data, but this person should have only one provider key.

Provider Specialty Type

This code represents the specialty of the primary care physician.

Medical Flag

Identifies whether the member has medical coverage (Y or N).

Pharmacy Flag

Identifies whether the member has pharmacy coverage (Y or N).